Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The primary objective was to determine superiority of dulaglutide 1.5 mg versus placebo in HbA1c change at 26 weeks. RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide 10 μg, or placebo (placebo-controlled period: 26 weeks). Patients were treated with metformin (1,500–3,000 mg) and pioglitazone (30–45 mg). Mean baseline HbA1c was 8.1% (65 mmol/mol). RESULTS: Least squares mean ± SE HbA1c change from baseline to the primary end point was −1.51 ± 0.06% (−16.5 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −1.30 ± 0.06% (−14.2 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, −0.99 ± 0.06% (−10.8 ± 0.7 mmol/mol) for exenatide, and −0.46 ± 0.08% (−5.0 ± 0.9 mmol/mol) for placebo. Both dulaglutide doses were superior to placebo at 26 weeks (both adjusted one-sided P < 0.001) and exenatide at 26 and 52 weeks (both adjusted one-sided P < 0.001). Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg than with placebo and exenatide (all P < 0.001). At 26 and 52 weeks, total hypoglycemia incidence was lower in patients receiving dulaglutide 1.5 mg than in those receiving exenatide; no dulaglutide-treated patients reported severe hypoglycemia. The most common gastrointestinal adverse events for dulaglutide were nausea, vomiting, and diarrhea. Events were mostly mild to moderate and transient. CONCLUSIONS: Both once-weekly dulaglutide doses demonstrated superior glycemic control versus placebo and exenatide with an acceptable tolerability and safety profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another analog of human of GLP-1, but in once weekly administration, was similarly found to be superior to exenatide twice daily in reducing HbA1C, −1.51% vs. −0.99%.18”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [18]
In the citing paper
“The most common adverse events (AEs) reported with GLP-1RAs were gastrointestinal disorders, such as nausea, diarrhea, vomiting, and abdominal pain, etc (7–9).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [8]
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“American Indian 40 (14) 37 (13) 38 (14) 20 (14)”
ResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Cited by
Items 301–396 of 396
Nauck, M. A., Punov, V., Kang, Y. M., & Lim, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70613 · Cited by 6
Buonanno, S., Gaggiano, C., Baldi, C., Cantarini, L., Frediani, B., & Gentileschi, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060284 · Cited by 3
Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?
Strong, J. L. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000113 · Cited by 3
Huang, J., Hua, F., Jiang, X., Zhang, X., Yang, M., Wang, L., Huang, X., & Luo, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130470 · Cited by 3
Gierlach, K., Nowak, K., Nowak, K., Olejarz, Z., Słowik, M., Drygała, Z., Wyrwał, J., Zielińska, Z., Nieć, M., & Krasuska, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.55.006 · Cited by 4
Mijajlovic, M. D., Bornstein, N. M., & Aleksić, V. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251326769 · Cited by 3
An alternative combination therapy for type 2 diabetes?
Østoft, S. H., & Christensen, M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60615-8 · Cited by 3
Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes
Matthews, J. E., Reinhardt, R. R., & Carr, M. C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174565 · Cited by 3
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedTang, C. C., Lim, J. K., Loo, L. S., Jung, H., Кониг, М., & Tham, L. S. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2373 · Cited by 4
Terui, S., Akamatsu, R., Arai, M., Inoue, R., Okuyama, T., Kyohara, M., Li, J., Tsuno, T., Miyashita, D., Togashi, Y., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01147-2 · Cited by 3
de la Peña, A., Loghin, C., Cui, X., Zhang, X., Kapitza, C., & Kelly, R. P. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12847 · Cited by 4
Incretin Based Therapies in Type 2 Diabetes Mellitus
Göksu, U. A., & Ünal, A. (2017) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2017.94830 · Cited by 6
Iwamoto, N., Matsui, A., Kazama, H., & Oura, T. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0346-4 · Cited by 3
Incretin-based therapies and cancer risk: a review of recent literature safety data
Scavone, C., Sportiello, L., Rafaniello, C., Fiorentino, S., Cimmaruta, D., Rossi, F., & Capuano, A. (2016) · Diabetes Management · Cited by 5
Xu, L., Yu, S. Q., Gao, L., Huang, Y., Wu, S., Yang, J., Sun, Y. X., Yang, Z., Chai, S. B., Zhang, Y., et al. (2020) · PubMed · doi:10.3967/bes2020.005 · Cited by 3
Тихоненко, Е. В., Arkhipova, A. G., Babenko, A. Y., & Shlyakhto, E. V. (2018) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2018-96-8-746-753 · Cited by 3
Visible-Light-Mediated Dehydrogenative Cross-Coupling of Azaarenes and Ethers
Song, J., Chen, W., Chen, X., Zhou, Y., Han, B., Wang, Y., Jia, H., Guo, K., Qiu, J., Wang, J., et al. (2025) · Chemistry · doi:10.3390/chemistry7040103 · Cited by 2
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
Wang, Y., Wang, S., Wang, W. J., Li, X., Leohr, J. K., Pires, V., Katz, M. L., Child, C. J., & Konrad, R. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70325 · Cited by 2
Liu, M. N., Wang, X., Li, M., Yang, E., Yang, A., Yuan, M., Dong, R., Qin, G., Liu, P., Li, C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102874 · Cited by 2
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 2
Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
Lee, I., & Kang, E. S. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.3.149 · Cited by 2
The effect of beinaglutide on visceral fat and bodyweight in obese type 2 diabetic patients
Wang, G., Wang, H., Zhang, F.-J., Jiao, A.-F., Li, Y.-Y., Zhang, J., Huang, Z., Gao, Y., Chi, Y., Ma, C., et al. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.98168 · Cited by 2
Bossi, A. C., Mori, V. D., Scaranna, C., Veronesi, G., Lepore, G., the ANDREW study group, Barbara, A., Rosalia, B., Antonio, B., Berzi, D., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00929-4 · Cited by 2
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets
Salmen, T., Pietroșel, V.-A., Urzica, F.-V., Visan, D.-E., Salmen, B.-M., Cîmpeanu, R.-C., Reurean‐Pintilei, D., Popoviciu, M. S., & Stoian, A. P. (2025) · Biomedicines · doi:10.3390/biomedicines13092306 · Cited by 1
Chang, L., Hassan, S., Chasse, J., Stern, G. M., Gabovitch, D., Zelle, D., Colling, C., Crossen, J., Aronson, S., Oates, M., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107359 · Cited by 1
Chen, Q., Chen, T., Lin, W., & Chen, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s585436 · Cited by 3
Violante-Ortiz, R. M., Rose, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005711 · Cited by 1
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Li, Y. C., Xu, X., Tuersun, A., Fan, X., Qin, M., Zhao, X., Abuduaini, S., Xing, H., & Chen, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108333 · Cited by 1
Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Araújo, L. M. D. M., Feguri, S., de Oliveira, T. L., Pedrosa, F. B., Guimarães, R. G., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61007 · Cited by 2
Albasheer, O. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072353980250418211500 · Cited by 1
Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS
Fernández, L. C., Pérez, J. S., Fernández, C. G., & Vela, N. S. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.2.art3 · Cited by 1
Tamaki, C., Takeuchi, M., Iwamoto, N., & Glaesner, W. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.146.215 · Cited by 1
Montanya, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_6 · Cited by 1
Kim, H. J. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.1.35 · Cited by 1
Dulaglutide – New in the Treatment of Type 2 Diabetes
Yegshatyan, L. V., Khachaturian, N., & Mkrtumyan, A. M. (2019) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2019-15-25-20-28 · Cited by 1
Dulaglutide‑pharmacological profile
Adamíková, A. (2019) · Interní medicína pro praxi · doi:10.36290/int.2019.011 · Cited by 1
Blood glucose, antidiabetic drugs, and risk of stroke
Lee, M., & Ovbiagele, B. I. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2020.00156 · Cited by 2
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
Gallwitz, B. (2015) · US Endocrinology · doi:10.17925/use.2015.11.1.47 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
and, C. R., & Petrie, J. R. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch6 · Cited by 1
Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes
Clements, J. N., Moore, K. G., & Shealy, K. M. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1098532
New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?
Seewoodhary, J., Wong, S. P. Y., & Ekanayake, K. P. (2015) · Practical Diabetes · doi:10.1002/pdi.1977
Real-World-Wirkungen von Dulaglutide bei Patienten, betreut in Diabetologischen Schwerpunktpraxen
Göke, R., Marck, C., Zerth, G., Ingo, N., & KLEPZIG, C. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-124422
Gallwitz, B. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0266-y
Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases
Abe, T. K., Nakanishi, M., Watanabe, O., Kawano, H., & Bando, H. (2018) · Diabetes Research - Open Journal · doi:10.17140/droj-4-136
Letter to the Editor: Dulaglutide efficacy
Sandrini, A. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.015
Liraglutide and Dulaglutide Have Comparable HbA1c Reduction in Emirati Patients with T2DM
Nada, A. M., & Younan, M. A. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.114008
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Efficacy of dulaglutide: an evidence-based review of its potential indications
Biryukova, E. V., & Solovyeva, I. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-18-30
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_44
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-2
Treating Type 2 Diabetes Mellitus
Migdal, A. L., & Abrahamson, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-1
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater
Tran, V., Tran, H., Demirel, S., & Thompson‐Moore, N. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221087933
Hert, S. G. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734529586.793559018
Effect of dulaglutide injection on weight beyond glycemic control: real-world observational study
Mohammed, A. G., & Odhaib, S. A. (2023) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2023.10643
Therapy Simplification with Dulaglutide in Elderly Patients: A Real World Study
Occhipinti, M., Baccetti, F., Bertoli, S., Cosimi, S., Casadidio, I., Cuccuro, I., Carlo, A. D., Gregori, G., Mori, M., Lacaria, E., et al. (2023) · Journal of Diabetes Research Review & Reports · doi:10.47363/jdrr/2023(5)168
Choice of Therapy in Obese Type 2 Diabetes
Jyotsna, V., & Deshmukh, S. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_2_22
Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Guo, L., Xi, Y., Li, L., Guo, K., Wu, J., Xu, J., Wang, Y., Wu, G., & Si, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15590
Morioka, T., Takeuchi, M., Ozeki, A., & Emoto, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15644
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety
Stasiak, M., Żyro, W., Woźniak, K., Żyro, K., Glapiński, F., & Woźniak, A. (2025) · Quality in Sport · doi:10.12775/qs.2025.42.60634
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Yuan, D., Vangaveti, V., Arojojoye, O. A., & Malabu, U. H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/2663671
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671494
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671485
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671491
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671497
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671488
Hung, C.-M., Hsu, C., Zeng, B.-S., Suen, M., Chen, J.-J., Zeng, B., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T.-Y., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062619
Nahabedian, M. Y., Deva, A. K., Ahmed, D., Fanzio, P. M., & Hammer, J. (2026) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojag054 · Cited by 1
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Adly, A. A. M., Ismail, E. A. R., Kader, M. S. E. M. A., Sadeq, M. R., & Salah, N. Y. (2026) · Diabetologia · doi:10.1007/s00125-026-06835-x
Mahmoud, N. M., Hussein, A., Mussa, B. M., & Abusnana, S. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261471399
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
Ali, M. A., Das, S., Kumar, R. R., & Rabindra, K. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26oct881
BindingDB Entry 50022803: Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
BindingDB (2026) · UC San Diego · doi:10.7270/q2028xcf
Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
Bovee, L. B., & Thirumalai, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00469-y
Metadata
- Authors
- Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M.
- Affiliations
- Redwood Clinic, Spokane, WA
- Texas Diabetes & Endocrinology (US)
- University of Hawaiʻi at Mānoa (US)
- American Telemedicine Center of Puerto Rico, San Juan, PR
- University Hospital Autonomous University of Nuevo León, Monterrey, Mexico
- Eli Lilly (United States) (US)
- Corresponding author
- Lakshmanan, Mark
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2159-2167
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2104252114
- Cited by
- 396
- References
- 24
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 26 · 2023: 27 · 2022: 15 · 2021: 25 · 2020: 31 · 2019: 31 · 2018: 34 · 2017: 38 · 2016: 47 · 2015: 44 · 2014: 10
- FWCI
- 37.26
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- dulaglutide, exenatide, type 2 diabetes, GLP-1 receptor agonists, pioglitazone, metformin, HbA1c, glycemic control, hypoglycemia, drug safety, combination therapy, dose comparison, HbA1c targets, weight gain, adverse events
- MeSH terms
- Pioglitazone, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Peptides, Recombinant Fusion Proteins, Venoms, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.